Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis

Cancer Investigation

Volumn 27, Issue 2, 2009, Pages 193-200

  Javle, Milind M ^a,b   Yang, Gary ^b   Nwogu, Chumy E ^b   Wilding, Gregory E ^b   O'Malley, Linda ^b   Vinjamaram, Sanjay ^b   Schiff, Michael D ^b   Nava, Hector R ^b   LeVea, Charles ^b   Clark, Kimberly R ^b   Prey, Joshua D ^b   Smith, Patrick F ^b,c   Pendyala, Lakshmi ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Capecitabine; Esophageal neoplasms; Gene expression; Neoadjuvant therapy; Oxaliplatin

Indexed keywords

CAPECITABINE; CARBOXYLESTERASE; OXALIPLATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DUODENAL ULCER BLEEDING; ESOPHAGITIS; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; GENE EXPRESSION; HEARTBURN; HUMAN; HUMAN TISSUE; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; STROKE; SYNCOPE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOXYLESTERASE; COMBINED MODALITY THERAPY; CYTIDINE DEAMINASE; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; THYMIDINE PHOSPHORYLASE;

EID: 60849110846     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802172093     Document Type: Article

References (42)

1. Fischel, J.L.; Etienne, M.C.; Formento, P.; et al. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998, 4, 2529-2535.
2. Oxaliplatin (Eloxatin) for advanced colon cancer. Med Lett Drugs Ther 2003, 45, 7-8.
3. Andre, T.; Boni, C.; Mounedji-Boudiaf, L.; et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350, 2343-2351.
4. Van, C.E.; Verslype, C.; Demedts, I. The treatment of advanced colorectal cancer: where are we now and where do we go? Best Pract Res Clin Gastroenterol 2002, 16, 319-330.
5. Khushalani, N.I.; Leichman, C.G.; Proulx, G.; et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002, 20, 2844-2850.
6. Ajani, J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006, 107, 221-231.
7. Cassidy, J. Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Clin Colorectal Cancer 2005, 5(Suppl 1), S47-S50.
8. Navarro, R.P.; Morrow, T.; Baran, R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag. Care Interface 2002, 15, 55-62.
9. Cassidy, J.; Tabernero, J.; Twelves, C.; et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004, 22, 2084-2091.
10. Scheithauer, W.; Kornek, G.V.; Raderer, M.; et al. Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol 2003, 21, 1307-1312.
11. Varma, R.; Hector, S.; Greco, W.R.; et al. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother. Pharmacol. 2006.
12. Hector, S.; Porter, C.W.; Kramer, D.L.; et al. Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol Cancer Ther 2004, 3, 813-822.
13. Toi, M.; Atiqur, R.M.; Bando, H.; et al. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005, 6, 158-166.
14. Hector, S.; Clark, K.; Murphy, M.; et al. The platinum drugs cisplatin and oxaliplatin induce carboxylesterase 2 gene expression in A2780 ovarian carcinoma cells. Proc. AACR 2003, 44, 368.
15. Judson, I.R.; Beale, P.J.; Trigo, J.M.; et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest N Drugs 1999, 17, 49-56.
16. Mandard, A.M.; Dalibard, F.; Mandard, J.C.; et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994, 73, 2680-2686.
17. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000, 92, 205-216.
18. Johnson, M.R.; Wang, K.; Smith, J.B.; et al. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000, 278, 175-184.
19. Mandard, A.M.; Dalibard, F.; Mandard, J.C.; et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994, 73, 2680-2686.
20. Chang, F.; Deere, H.; Mahadeva, U.; et al. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol 2008, 129, 252-262.
21. Levi, F.; Metzger, G.; Massari, C.; et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet 2000, 38, 1-21.
22. Ajani, J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006, 107, 221-231.
23. Cunningham, D.; Starling, N.; Rao, S.; et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358, 36-46.
24. Kelsen, D.P.; Multimodality therapy of local regional esophageal cancer. Semin Oncol 2005, 32, S6-10.
25. Cunningham, D.; Maroun, J.; Vanhoefer, U.; et al. Optimizing the use of irinotecan in colorectal cancer. Oncologist 2001, 6 Suppl 4, 17-23.
26. Ajani, J.A.; Faust, J.; Yao, J.; et al. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncol (Williston Park) 2003, 17, 20-22.
27. Pasini, F.; de, M.G.; Pedrazzani, C.; et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005, 16, 1133-1139.
28. Rigas, J.R.; Dragnev, K.H.; Bubis, J.A. Docetaxel in the treatment of esophageal cancer. Semin. Oncol. 2005, 32, S39-S51.
29. Berger, A.C.; Farma, J.; Scott, W.J.; et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005, 23, 4330-4337.
30. Hammoud, Z.T.; Kesler, K.A; Ferguson, M.K.; et al. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. Dis Esophagus 2006, 19, 69-72.
31. Joshi M.B.; Shirota Y.; Danenberg K.D.; et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005, 11, 2215-2221.
32. Luthra, R.; Luthra, M.G.; Izzo, J.; et al. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin. Oncol 2006, 33 Suppl 11, 2-5.
33. Yamamoto, M.; Tsujinaka, T.; Shiozaki, H.; et al. Metallothionein expression correlates with the pathological response of patients with esophageal cancer undergoing preoperative chemoradiation therapy. Oncol. 1999, 56, 332-337.
34. Wu, M.Y.; Zhuang, C.X.; Yang, H.X.; et al. Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study.World J Gastroenterol 2004, 10, 476-480.
35. Nakamura, T.; Hayashi, K.; Ota, M.; et al. Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis. Esophagus 2004, 17, 315-321.
36. Warnecke-Eberz, U.; Hokita, S.; Xi H.; et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005, 13, 1241-1246.
37. Kajiyama, Y.; Hattori, K.; Tomita, N.; et al. Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus: multivariate analysis of predictive factors and p53 overexpression. Dis. Esophagus 2002, 15, 61-66.
38. Luthra, R.; Wu, T.T.; Luthra, M.G.; et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006, 24, 259-267.
39. Leichman, L.; Lawrence, D.; Leichman, C.G.; et al. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J Chemother 2006, 18, 514-524.
40. Stoehlmacher, J.; Lenz, H.J. Implications of genetic testing in the management of colorectal cancer. Am J Pharmacogenomics 2003, 3, 73-88.
41. Xi, H.; Baldus, S.E.; Warnecke-Eberz, U.; et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005, 11, 8341-8347.
42. Schneider, S.; Uchida, K.; Brabender, J.; et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005, 200, 336-344.